Biofil Chemicals and Pharmaceuticals Limited
NSE: BIOFILCHEM BSE: BIOFILCHEM
NSE
32.83
-0.20 (-0.61%)
Prev Close
33.03
Open Price
33.01
Volume
12,759
Today Low / High
32.61 / 33.9
52 WK Low / High
32.52 / 62.98
Range
31 - 34
BSE
33.05
-0.12 (-0.36%)
Prev Close
33.17
Open Price
33.06
Volume
441
Today Low / High
33 / 33.37
52 WK Low / High
32.59 / 63.11
Range
31 - 35
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 32.83 (target range: 31 - 34), reflecting a change of -0.2 (-0.60551%). On the BSE, it is listed at 33.05 (target range: 31 - 35), showing a change of -0.12 (-0.36177%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
19 Dec
33.01
-0.55%
18 Dec
34.40
-3.98%
17 Dec
34.83
-2.93%
16 Dec
35.00
-1.60%
15 Dec
33.99
3.06%
12 Dec
33.94
-0.82%
11 Dec
34.00
-0.26%
10 Dec
34.00
-1.53%
09 Dec
33.66
0.42%
08 Dec
35.80
-5.98%
05 Dec
34.26
2.48%
04 Dec
34.88
-2.58%
03 Dec
36.80
-8.78%
02 Dec
38.25
-6.27%
01 Dec
37.20
0.22%
28 Nov
38.60
-3.55%
27 Nov
38.35
-2.53%
26 Nov
37.01
0.86%
25 Nov
37.21
-0.56%
24 Nov
38.10
-0.26%
Biofil Chemicals and Pharmaceuticals Limited Graph
Biofil Chemicals and Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Biofil Chemicals and Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 32.83, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 33.05 | 33.38 | 30.04 - 36.72 |
| 33.71 | 26.97 - 40.45 | ||
| 34.04 | 23.83 - 44.25 | ||
| Bearish Scenario | 33.05 | 32.72 | 29.45 - 35.99 |
| 32.39 | 25.91 - 38.87 | ||
| 32.06 | 22.44 - 41.68 |
Overview of Biofil Chemicals and Pharmaceuticals Limited
ISIN
INE829A01014
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
14,910
Market Cap
534,268,854
Last Dividend
0
Official Website
IPO Date
2017-07-27
DCF Diff
35.03
DCF
-2
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 33.40 Cr | 31.31 Cr | 2.09 Cr | 0.0626 | 0.00 Cr | 0.42 Cr | 0.47 Cr | 0.56 Cr | 0.34 | 1.15 Cr | 0.0167 |
| 2024-03-31 | 40.04 Cr | 37.51 Cr | 2.53 Cr | 0.0631 | 0.00 Cr | 0.14 Cr | 0.42 Cr | 0.71 Cr | 0.44 | 1.31 Cr | 0.0177 |
| 2023-03-31 | 30.04 Cr | 27.47 Cr | 2.56 Cr | 0.0853 | 0.00 Cr | 0.14 Cr | 0.74 Cr | 0.56 Cr | 0.34 | 1.26 Cr | 0.0187 |
| 2022-03-31 | 22.38 Cr | 19.52 Cr | 2.87 Cr | 0.1280 | 0.00 Cr | 0.19 Cr | 0.91 Cr | 0.70 Cr | 0.43 | 1.48 Cr | 0.0312 |
| 2021-03-31 | 35.75 Cr | 32.48 Cr | 3.32 Cr | 0.0930 | 0.01 Cr | 0.18 Cr | 1.19 Cr | 1.24 Cr | 0.76 | 2.40 Cr | 0.0347 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.13 Cr | 50.96 Cr | 32.18 Cr | 18.7816 Cr | 0.47 Cr | 0.34 Cr | 3.34 Cr | 8.34 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 31.8477 Cr |
| 2024-03-31 | 2.28 Cr | 47.08 Cr | 28.88 Cr | 18.2028 Cr | 0.44 Cr | -1.84 Cr | 2.55 Cr | 8.62 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 28.5245 Cr |
| 2023-03-31 | 0.04 Cr | 31.41 Cr | 14.10 Cr | 17.3015 Cr | 0.52 Cr | 0.48 Cr | 1.21 Cr | 9.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 13.7255 Cr |
| 2022-03-31 | 0.15 Cr | 18.73 Cr | 1.89 Cr | 16.8377 Cr | 0.46 Cr | 0.32 Cr | 1.29 Cr | 9.42 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 1.4947 Cr |
| 2021-03-31 | 0.44 Cr | 33.24 Cr | 17.11 Cr | 16.1291 Cr | 0.43 Cr | -0.01 Cr | 4.34 Cr | 9.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 16.7531 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -1.9236 Cr | -0.1001 Cr | -0.0045 Cr | -2.0237 Cr | -2.0282 Cr | 0.2553 Cr | -0.1001 Cr | 0.7362 Cr | 0.0324 Cr | 0.0000 Cr | -0.7917 Cr |
| 2024-03-31 | 2.3937 Cr | -0.0229 Cr | -0.1249 Cr | 2.3708 Cr | 2.2459 Cr | 2.2835 Cr | -0.0229 Cr | 0.7092 Cr | -0.0834 Cr | 0.0000 Cr | -1.3363 Cr |
| 2023-03-31 | -0.1118 Cr | -0.0106 Cr | 0.0151 Cr | -0.1224 Cr | -0.1073 Cr | 0.0376 Cr | -0.0106 Cr | 0.7930 Cr | 0.0576 Cr | 0.0000 Cr | 0.0797 Cr |
| 2022-03-31 | -0.2199 Cr | -0.0699 Cr | -0.0058 Cr | -0.2898 Cr | -0.2956 Cr | 0.1449 Cr | -0.0699 Cr | 0.6984 Cr | 0.0348 Cr | 0.0000 Cr | 3.0514 Cr |
| 2021-03-31 | 1.1109 Cr | -0.0961 Cr | -0.8303 Cr | 0.5442 Cr | 0.1845 Cr | 0.4405 Cr | -0.5667 Cr | 1.9189 Cr | -0.7622 Cr | 0.0000 Cr | -2.6524 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 13.54 Cr | 13.17 Cr | 0.37 Cr | 0.0273 | 0.05 Cr | 0.08 Cr | 0.05 | 0.18 Cr | 0.0062 |
| 2025-06-30 | 6.43 Cr | 5.99 Cr | 0.44 Cr | 0.0689 | -0.06 Cr | 2.41 Cr | 1.48 | 2.84 Cr | 0.3748 |
| 2025-03-31 | 8.35 Cr | 7.80 Cr | 0.55 Cr | 0.0655 | 0.02 Cr | 0.20 Cr | 0.12 | 0.34 Cr | 0.0239 |
| 2024-12-31 | 14.20 Cr | 13.62 Cr | 0.57 Cr | 0.0403 | 0.21 Cr | 0.16 Cr | 0.10 | 0.33 Cr | 0.0116 |
| 2024-09-30 | 2.41 Cr | 2.05 Cr | 0.36 Cr | 0.1505 | 0.03 Cr | 0.02 Cr | 0.02 | 0.14 Cr | 0.0101 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 0.23 Cr | 0.13 Cr | 0.36 Cr | 40.77 Cr | 3.48 Cr | 48.42 Cr | 6.95 Cr | 55.36 Cr | 34.06 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 0.26 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -18.78 Cr |
| 2025-03-31 | 0.13 Cr | 0.12 Cr | 0.26 Cr | 38.32 Cr | 3.34 Cr | 42.55 Cr | 8.34 Cr | 50.96 Cr | 32.18 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 0.22 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -18.40 Cr |
| 2024-09-30 | 0.16 Cr | 0.06 Cr | 0.22 Cr | 25.51 Cr | 6.80 Cr | 33.61 Cr | 8.43 Cr | 42.04 Cr | 23.64 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 2.41 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 0.20 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 0.16 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 0.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 0.17 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,744.90 | ₹4,186,599,589,153.00 | ₹2,768,881.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,478.50 | ₹1,719,838,195,530.00 | ₹785,191.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,800.30 | ₹1,286,194,205,632.00 | ₹150,391.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,278.20 | ₹1,064,117,509,455.00 | ₹1,209,451.00 |
| Lupin Limited | LUPIN | ₹2,125.80 | ₹971,062,901,795.00 | ₹595,983.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹919.60 | ₹925,332,777,204.00 | ₹799,832.00 |
| Mankind Pharma Limited | MANKIND | ₹2,172.10 | ₹896,653,896,891.00 | ₹491,290.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,225.10 | ₹711,540,068,337.00 | ₹1,396,498.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,555.50 | ₹664,243,357,500.00 | ₹51,668.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,045.20 | ₹564,258,099,506.00 | ₹2,843,487.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,992.10 | ₹562,172,231,609.00 | ₹527,752.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,424.80 | ₹361,477,769,806.00 | ₹169,772.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,632.60 | ₹328,905,523,742.00 | ₹110,006.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,805.70 | ₹282,864,631,249.00 | ₹90,439.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,385.00 | ₹262,547,317,250.00 | ₹43,519.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,411.10 | ₹229,292,699,676.00 | ₹3,916,644.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,091.50 | ₹227,287,500,000.00 | ₹5,946.00 |
| Eris Lifesciences Limited | ERIS | ₹1,571.60 | ₹214,078,465,896.00 | ₹36,657.00 |
| Cohance Lifesciences Limited | COHANCE | ₹538.45 | ₹205,993,276,533.00 | ₹739,838.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,044.00 | ₹205,842,739,116.00 | ₹80,404.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,087.10 | ₹172,303,648,689.00 | ₹385,335.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹859.90 | ₹169,024,630,328.00 | ₹65,161.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹916.75 | ₹164,198,973,323.00 | ₹828,152.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,926.90 | ₹146,466,937,022.00 | ₹23,449.00 |
| Granules India Limited | GRANULES | ₹583.40 | ₹141,572,928,914.00 | ₹2,092,706.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹900.65 | ₹110,492,956,076.00 | ₹28,666.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,662.00 | ₹93,985,700,884.00 | ₹8,085.00 |
| Strides Pharma Science Limited | STAR | ₹930.80 | ₹85,794,362,191.00 | ₹1,135,299.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹747.10 | ₹67,722,593,347.00 | ₹138,130.00 |
| FDC Limited | FDC | ₹411.00 | ₹66,914,944,524.00 | ₹44,533.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹427.20 | ₹65,405,199,178.00 | ₹79,062.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹324.75 | ₹63,515,194,746.00 | ₹217,012.00 |
| Sequent Scientific Limited | SEQUENT | ₹210.32 | ₹52,542,945,612.00 | ₹611,339.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹143.82 | ₹46,672,694,786.00 | ₹5,389,949.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹404.95 | ₹44,125,484,062.00 | ₹842,528.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹787.05 | ₹39,918,471,590.00 | ₹47,648.00 |
| Innova Captab Limited | INNOVACAP | ₹689.25 | ₹39,442,282,313.00 | ₹23,459.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,343.40 | ₹38,757,527,751.00 | ₹4,275.00 |
| Suven Life Sciences Limited | SUVEN | ₹171.00 | ₹37,689,428,565.00 | ₹168,450.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹349.00 | ₹34,998,594,594.00 | ₹19,683.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹381.55 | ₹34,824,068,500.00 | ₹204,900.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹449.80 | ₹31,668,506,350.00 | ₹12,331.00 |
| Hikal Limited | HIKAL | ₹237.11 | ₹29,235,840,833.00 | ₹187,426.00 |
Key Executives
Head of Administration
Joseph Chacko
Gender: Not Specified
Year Born: 1961
Company Secretary & Compliance officer
Apoorv Jain
Gender: male
Year Born:
MD & Chairman
Ketan Shah
Gender: male
Year Born: 1961
Chief Financial Officer
Pavan Singh Rajput
Gender: male
Year Born: 1991
Chief Chemist
Vinayak Bhopte
Gender: Not Specified
Year Born: 1974
FAQs about Biofil Chemicals and Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Ketan Shah.
What is the current market price of the stock?
The current price is ₹32.83.
What is the 52-week price range?
The range is ₹32.52-62.98.
What is the market capitalization of the company?
The market capitalization is ₹53.43 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 19.20.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Biofil Chemicals and Pharmaceuticals Limited (ISIN: INE829A01014) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹53.43 crores and an average daily volume of 14,910 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.